Literature DB >> 26277892

Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Ming You1, Guanjun Dong1, Fanlin Li1, Feiya Ma1, Jing Ren1, Yujun Xu1, Huimin Yue1, Ruijing Tang1, Deshan Ren1, Yayi Hou1,2.   

Abstract

A hallmark of systemic lupus erythematosus (SLE) is the consistent production of various auto-antibodies by auto-reactive B cells. Interferon-α (IFN-α) signaling is highly activated in SLE B cells and plays a vital role in the antibody response by B cells. Previous studies have shown that CD180-negative B cells, which are dramatically increased in SLE patients, are responsible for the production of auto-antibodies. However, the association between CD180 and IFN-α signaling remains unknown. In the present study, we explored the effect of CD180 on regulating the activation of IFN-α signaling in B cells. We found that the number of CD180-negative B cells was increased in MRL/Mp-Fas(lpr/lpr) lupus-prone mice compared with wild-type mice. Phenotypic analysis showed that CD180-negative B cells comprised CD138+ plasmablast/plasma cells and GL-7+ germinal center (GC) B cells. Notably, ligation of CD180 significantly inhibited the IFN-α-induced phosphorylation of signal transducer and activator of transcription 2 (STAT-2) and expression of IFN-stimulated genes (ISGs) in a Lyn-PI3K-BTK-dependent manner in vitro. Moreover, ligation of CD180 could also inhibit IFN-α-induced ISG expression in B cells in vivo. Furthermore, the Toll-like receptor 7 and Toll-like receptor 9 signaling pathways could significantly downregulate CD180 expression and modulate the inhibitory effect of CD180 signaling on the activation of IFN-α signaling. Collectively, our results highlight the close association between the increased proportion of CD180-negative B cells and the activation of IFN-α signaling in SLE. Our data provide molecular insight into the mechanism of IFN-α signaling activation in SLE B cells and a potential therapeutic approach for SLE treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26277892      PMCID: PMC5301152          DOI: 10.1038/cmi.2015.61

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  59 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

2.  Pathogenesis of lupus-like nephritis through autoimmune antibody produced by CD180-negative B lymphocytes in NZBWF1 mouse.

Authors:  Kazuko Fujita; Yoshikiyo Akasaka; Taku Kuwabara; Bing Wang; Kaoru Tanaka; Itaru Kamata; Tomoko Yokoo; Toshio Kinoshita; Ami Iuchi; Yuri Akishima-Fukasawa; Yukio Ishikawa; Motonari Kondo; Toshiharu Ishii
Journal:  Immunol Lett       Date:  2012-02-28       Impact factor: 3.685

3.  Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus.

Authors:  Deshan Ren; Fei Liu; Guanjun Dong; Ming You; Jianjian Ji; Yahong Huang; Yayi Hou; Hongye Fan
Journal:  Cell Mol Immunol       Date:  2015-07-06       Impact factor: 11.530

4.  Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice.

Authors:  Alexis Mathian; Mike Gallegos; Virginia Pascual; Jacques Banchereau; Sophie Koutouzov
Journal:  Eur J Immunol       Date:  2011-02-11       Impact factor: 5.532

5.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

6.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

Review 7.  Regulation of autoreactive B cell responses to endogenous TLR ligands.

Authors:  Ana Maria Avalos; Liliana Busconi; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

8.  Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression.

Authors:  K Miyake; R Shimazu; J Kondo; T Niki; S Akashi; H Ogata; Y Yamashita; Y Miura; M Kimoto
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

9.  IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production.

Authors:  Gagik Oganesyan; Supriya K Saha; Eric M Pietras; Beichu Guo; Andrea K Miyahira; Brian Zarnegar; Genhong Cheng
Journal:  J Biol Chem       Date:  2007-10-09       Impact factor: 5.157

10.  The molecular mechanism of B cell activation by toll-like receptor protein RP-105.

Authors:  V W Chan; I Mecklenbräuker; I Su; G Texido; M Leitges; R Carsetti; C A Lowell; K Rajewsky; K Miyake; A Tarakhovsky
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more
  6 in total

1.  CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response.

Authors:  Zhenghao Wu; Junjie Zhou; Yunxiao Xiao; Jie Ming; Jing Zhou; Fang Dong; Xiaoqi Zhou; Zhuoshuo Xu; Xiangwang Zhao; Ping Lei; Tao Huang
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

2.  CD180 Ligation Inhibits TLR7- and TLR9-Mediated Activation of Macrophages and Dendritic Cells Through the Lyn-SHP-1/2 Axis in Murine Lupus.

Authors:  Yonghong Yang; Cuiling Wang; Panpan Cheng; Xiaobei Zhang; Xuehui Li; Yuan Hu; Feihong Xu; Feng Hong; Guanjun Dong; Huabao Xiong
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

3.  Toll-Like Receptor Mediated Activation of Natural Autoantibody Producing B Cell Subpopulations in an Autoimmune Disease Model.

Authors:  Szabina Erdő-Bonyár; Judit Rapp; Tünde Minier; Gábor Ráth; József Najbauer; László Czirják; Péter Németh; Timea Berki; Diána Simon
Journal:  Int J Mol Sci       Date:  2019-12-06       Impact factor: 5.923

Review 4.  Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases.

Authors:  Yuhong Zhai; Jun Yang; Jing Zhang; Jian Yang; Qi Li; Tao Zheng
Journal:  Int J Med Sci       Date:  2021-01-14       Impact factor: 3.738

5.  Comparative Analysis on Abnormal Methylome of Differentially Expressed Genes and Disease Pathways in the Immune Cells of RA and SLE.

Authors:  Qinghua Fang; Tingyue Li; Peiya Chen; Yuzhe Wu; Tingting Wang; Lixia Mo; Jiaxin Ou; Kutty Selva Nandakumar
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

6.  Analysis of PI3K Pathway Associated Molecules Reveals Dysregulated Innate and Adaptive Functions of B Cells in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Diána Simon; Szabina Erdő-Bonyár; Judit Rapp; Péter Balogh; Tünde Minier; Gabriella Nagy; László Czirják; Tímea Berki
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.